| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVITED REVIEW
Departments of 1Biochemistry, 2Internal Medicine, and 3Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa
Epoxyeicosatrienoic acids (EETs), which function primarily as autocrine and paracrine mediators in the cardiovascular and renal systems, are synthesized from arachidonic acid by cytochrome P-450 epoxygenases. They activate smooth muscle large-conductance Ca2+-activated K+ channels, producing hyperpolarization and vasorelaxation. EETs also have anti-inflammatory effects in the vasculature and kidney, stimulate angiogenesis, and have mitogenic effects in the kidney. Many of the functional effects of EETs occur through activation of signal transduction pathways and modulation of gene expression, events probably initiated by binding to a putative cell surface EET receptor. However, EETs are rapidly taken up by cells and are incorporated into and released from phospholipids, suggesting that some functional effects may occur through a direct interaction between the EET and an intracellular effector system. In this regard, EETs and several of their metabolites activate peroxisome proliferator-activated receptor 
(PPAR) and PPAR
, suggesting that some functional effects may result from PPAR activation. EETs are metabolized primarily by conversion to dihydroxyeicosatrienoic acids (DHETs), a reaction catalyzed by soluble epoxide hydrolase (sEH). Many potentially beneficial actions of EETs are attenuated upon conversion to DHETs, which do not appear to be essential under routine conditions. Therefore, sEH is considered a potential therapeutic target for enhancing the beneficial functions of EETs.
soluble epoxide hydrolase; eicosanoids; dihydroxyeicosatrienoic acids; cytochrome P-450; peroxisome proliferator-activated receptor
This article has been cited by other articles:
|
|
 |
|
  E. Barbosa-Sicard, T. Fromel, B. Keseru, R. P. Brandes, C. Morisseau, B. D. Hammock, T. Braun, M. Kruger, and I. Fleming Inhibition of the Soluble Epoxide Hydrolase by Tyrosine Nitration J. Biol. Chem., October 9, 2009; 284(41): 28156 - 28163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-N. Zhang, J. Vincelette, Y. Cheng, U. Mehra, D. Chen, S.-K. Anandan, R. Gless, H. K. Webb, and Y.-X. Wang Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Gross, K. M. Gauthier, J. Moore, W. B. Campbell, J. R. Falck, and K. Nithipatikom Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H47 - H52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Buczynski, D. S. Dumlao, and E. A. Dennis Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology J. Lipid Res., June 1, 2009; 50(6): 1015 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res., April 1, 2009; 50(Supplement): S52 - S56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Behm, A. Ogbonna, C. Wu, C. L. Burns-Kurtis, and S. A. Douglas Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Hercule, W.-H. Schunck, V. Gross, J. Seringer, F. P. Leung, S. M. Weldon, A. Ch. da Costa Goncalves, Y. Huang, F. C. Luft, and M. Gollasch Interaction Between P450 Eicosanoids and Nitric Oxide in the Control of Arterial Tone in Mice Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Morin, M. Sirois, V. Echave, E. Rizcallah, and E. Rousseau Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung Am J Physiol Lung Cell Mol Physiol, January 1, 2009; 296(1): L130 - L139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Fife, Y. Liu, K. R. Schmelzer, H.-J. Tsai, I.-H. Kim, C. Morisseau, B. D. Hammock, and D. L. Kroetz Inhibition of Soluble Epoxide Hydrolase Does Not Protect against Endotoxin-Mediated Hepatic Inflammation J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keseru, E. Barbosa-Sicard, R. Popp, B. Fisslthaler, A. Dietrich, T. Gudermann, B. D. Hammock, J. R. Falck, N. Weissmann, R. Busse, et al. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response FASEB J, December 1, 2008; 22(12): 4306 - 4315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Webler, U. R. Michaelis, R. Popp, E. Barbosa-Sicard, A. Murugan, J. R. Falck, B. Fisslthaler, and I. Fleming Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1292 - C1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. MacEachran, B. A. Stanton, and G. A. O'Toole Cif Is Negatively Regulated by the TetR Family Repressor CifR Infect. Immun., July 1, 2008; 76(7): 3197 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sura, R. Sura, A. E. EnayetAllah, and D. F. Grant Distribution and Expression of Soluble Epoxide Hydrolase in Human Brain J. Histochem. Cytochem., June 1, 2008; 56(6): 551 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dragin, Z. Shi, R. Madan, C. L. Karp, M. A. Sartor, C. Chen, F. J. Gonzalez, and D. W. Nebert Phenotype of the Cyp1a1/1a2/1b1(-/-) Triple-Knockout Mouse Mol. Pharmacol., June 1, 2008; 73(6): 1844 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gross, K. M. Gauthier, J. Moore, J. R. Falck, B. D. Hammock, W. B. Campbell, and K. Nithipatikom Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2838 - H2844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, V. R. Tuniki, S. Anjaiah, J. R. Falck, C. J. Hillard, and W. B. Campbell Characterization of Epoxyeicosatrienoic Acid Binding Site in U937 Membranes Using a Novel Radiolabeled Agonist, 20-125I-14,15-Epoxyeicosa-8(Z)-Enoic Acid J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1019 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Larsen, D. D. Gutterman, A. Sato, K. Toyama, W. B. Campbell, D. C. Zeldin, V. L. Manthati, J. R. Falck, and H. Miura Hydrogen Peroxide Inhibits Cytochrome P450 Epoxygenases: Interaction Between Two Endothelium-Derived Hyperpolarizing Factors Circ. Res., January 4, 2008; 102(1): 59 - 67. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
